PRME
Prime Medicine Reports Q2 2026 Results with WD IND Clearances and New AATD IND Target
Prime Medicine secured global regulatory clearance for its Wilson disease program. The company also reported a favorable arbitration outcome for its Alpha-1 Antitrypsin Deficiency rights and provided updated financial guidance, highlighting progress towards a potential BLA submission and IND for a n…